Highest-materiality recent filing
Artiva CFO departs; CEO assumes financial duties; Miralles becomes President
CFO Thad Huston to leave May 22; receives $135k cash severance and 9 months COBRA; search begun.
71% ACR50 response in company-sponsored Phase 2a at 6 months (5/7 patients); no relapses or new immunomodulatory agents.
Artiva Biotherapeutics raises ~$300M in common stock and pre-funded warrant offering
Priced 23,871,526 shares at $11.52/share and 2,170,138 pre-funded warrants at $11.5199 each.
Artiva reports FY2025 net loss of $83.9M; cash $108M into Q2 2027
Net loss $83.9M vs $65.4M in 2024; R&D spend $69.5M (up 38% YoY); revenue zero.
Artiva Biotherapeutics appoints Thad Huston as CFO effective Feb 18, 2026
Thad Huston appointed CFO, principal financial and accounting officer, effective Feb 18, 2026.
Artiva Biotherapeutics appoints former AbbVie SVP Elaine Sorg as Class I director
Elaine Sorg appointed as Class I director on Feb 18, 2026, term expiring at 2028 annual meeting.
Artiva Biotherapeutics exchanges underwater options for RSUs for CEO and COO
CEO Fred Aslan surrendered 869,136 options (566,470 vested, 302,666 unvested) for equivalent RSUs with new vesting.
Artiva Q3 net loss $21.5M; AlloNK gets FDA Fast Track for RA
Over 100 patients dosed with AlloNK; FDA Fast Track Designation for refractory RA with rituximab.
32 patients dosed with AlloNK + anti-CD20 mAb as outpatients at community rheumatology sites; no CRS, ICANS or GvHD.
Artiva reports Q2 net loss $21.3M; cash runway into Q2 2027; autoimmune trial progress
Net loss of $21.3M for Q2 2025 vs $17.8M in Q2 2024; R&D expenses $17.9M (up from $12.3M).
Artiva stockholders approve 1.2M share increase to 2024 equity plan, re-elect director Baker
Amendment to 2024 Equity Incentive Plan approved, adding 1,214,580 shares to the share reserve; total now up to 7,001,185 shares.
Artiva reports Q1 net loss $20.3M; AlloNK IND cleared for autoimmune basket trial
Cash, cash equivalents and investments of $166.0M as of March 31, 2025; cash runway into Q2 2027.
Artiva reports 2024 net loss of $65.4M; cash $185.4M; autoimmune data expected H1 2025
Net loss of $65.4M in 2024 vs net income of $28.7M in 2023; no collaboration revenue vs $32.9M prior year.
Artiva appoints Daniel Baker to board; forms Clinical Strategy Committee
Daniel Baker, Ph.D. appointed as Class I director effective Jan 28, 2025; term expires at 2025 annual meeting.
Artiva Q3 2024 net loss $17.5M; cash $199.6M; AlloNK data expected H1 2025
Net loss of $17.5M for Q3 2024 vs net income of $11.3M a year ago as collaboration revenue ended.
Artiva appoints Alison Moore Ph.D. as Class III director and committee member
Alison Moore appointed as Class III director with term expiring at 2027 annual meeting; also joins Technical Operations Committee.
Artiva reports Q2 net loss $17.8M; IPO raises $179M extending cash runway through 2026
IPO in July 2024 raised $179M gross; cash $46.6M pre-IPO, runway now through 2026.
Artiva Biotherapeutics files amended charter and bylaws upon IPO closing
Amended and restated certificate of incorporation filed with Delaware Secretary of State on July 22, 2024, effective prior to IPO closing.
On May 18, 2026, Diego Miralles, M.D. resigned as a member of the Board of Directors (the “Board”) of Artiva Biotherapeutics, Inc. (the “Company”), effective May 18, 2026
On May 18, 2026 (the “Effective Date”), Fred Aslan, M.D. resigned as President of the Company in connection with Dr. Miralles’s appointment as President and Head of Research and Development of the Company as described below.
On May 18, 2026, Thad Huston and the Company agreed to Mr. Huston’s separation from his position as Chief Financial Officer and principal financial and accounting officer of the Company, effective May 22, 2026
On January 28, 2025, the Board of Directors (the “Board”) of Artiva Biotherapeutics, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Daniel Baker, Ph.D. as (i) a Class I director of the Company, with a term of office expiring at the 2025 annual meeting of stockholders
appointed Alison Moore, Ph.D. as (i) a Class III director of the Company, with a term of office expiring at the 2027 annual meeting of stockholders and (ii) a member of the Technical Operations Committee of the Board
Max materiality 0.85 · Median 0.57 · Most common event earnings